Unknown PHASE1 INTERVENTIONAL 1-arm NCT00799799

Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells

Sponsor: University of Bologna

Interventions NK cells

Updated 5 times since 2017 Last updated: Sep 23, 2009 Started: Oct 31, 2005 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00799799, this PHASE1 trial focuses on Myeloblastic Leukemia and remains ongoing. Sponsored by University of Bologna, it has been updated 5 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Bologna

Data source: University of Bologna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bologna, Italy